Cargando…
ODP259 Evaluating the Efficacy and Safety of Long-Acting GLP-1 Receptor Agonist in T1DM Patients
INTRODUCTION: GLP-1 receptor agonist is a medication class that mimics the endogenous incretin hormone GLP-1. Short-acting GLP-1 agents were studied as adjunct therapies in type 1 diabetes (T1DM) but not approved due to concern of increased diabetic ketoacidosis (DKA) risk. Long-acting GLP-1 medicat...
Autores principales: | Mohandas, Deene, Gao, Catherine, Calma, Jamie, Basina, Marina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628966/ http://dx.doi.org/10.1210/jendso/bvac150.706 |
Ejemplares similares
-
Covid Lockdown Impact on Type 1 Diabetes Health and Well-Being
por: Calma, Jamie, et al.
Publicado: (2021) -
ODP171 Choosing GLP-1RA Over Insulin for Patients with Type 2 Diabetes and Severe Hyperglycemia
por: Mamtani, Raashi, et al.
Publicado: (2022) -
ODP183 Diabetic Ketoacidosis Precipitated by Ketogenic Diet and SGLT-2 Inhibitor Use in an Individual with T2DM
por: Mason, Timothy, et al.
Publicado: (2022) -
FRI657 Case Series On GLP-1 Receptor Agonist Related Acute Pancreatitis
por: Kumar Kulkarni, Abhigna Uday, et al.
Publicado: (2023) -
THU334 Trends In GLP-1 Agonist Utilization In Diabetics With And Without Vascular Disease
por: Sargin, Pinar, et al.
Publicado: (2023)